Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Irene M. Ghobrial"'
Publikováno v:
Leukemia & Lymphoma. 57:2699-2701
Lymphoplasmacytic lymphoma (LPL) is characterized by involvement of the bone marrow and other sites by a monoclonal population of B-cells, lymphoplasmacytoid and plasma cells. In over 95% of LPL ca...
Autor:
Irene M. Ghobrial, Matthew Weinstock
Publikováno v:
Leukemia & Lymphoma. 54:1135-1141
Extramedullary disease (EMD), defined as a clonal plasmacytic infiltrate at anatomic sites distant from the bone marrow or adjacent soft tissue in a patient with underlying multiple myeloma, is present in a significant percentage of patients with mul
Autor:
Irene M. Ghobrial, Giada Bianchi
Publikováno v:
Leukemia & Lymphoma. 54:229-241
The prognosis of patients with multiple myeloma (MM) has radically changed over the past two decades mostly due to the introduction of novel pharmacologic treatments such as thalidomide, bortezomib and lenalidomide. These drugs were the first new ant
Autor:
Hong Wang, Ana B. Oton, Irene M. Ghobrial, Ann S. LaCasce, Xavier Leleu, Kenneth A. Foon, Mona F. Melhem, Diane George
Publikováno v:
Leukemia & Lymphoma. 49:1738-1744
We sought to determine the clinical and immunohistopathological prognostic factors for overall survival (OS) in adult patients with post-transplant lymphoproliferative disorders (PTLDs). Eighty-four patients diagnosed with PTLDs between 1980 and 2004
Autor:
Mark R Pittlekow, Irene M. Ghobrial, Paul J. Kurtin, Kay M. Ristow, Stephen M. Ansell, Guangzhi Qu, Roger H. Weenig
Publikováno v:
Leukemia & Lymphoma. 46:703-708
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of cytotoxic T-cell lymphoma. The objective of this study was to characterize the clinical presentation, treatment, and prognosis of patients with SPTCL. Twenty-one patients with S
Autor:
Kay M. Ristow, Suzan M. Geyer, Irene M. Ghobrial, Thomas M. Habermann, William R. Macon, Stephen M. Ansell, Christopher G.A. McGregor
Publikováno v:
Leukemia & Lymphoma. 46:191-196
To assess the effect of rituximab therapy and other prognostic factors on overall survival in patients with post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation, 30 consecutive patients diagnosed with PTLD between 19